HIV Treatment Biktarvy Approved to Treat Younger Children
October 18, 2021Dupixent Asthma Indication Expanded
October 20, 2021October 19, 2021 – Merck has recalled one lot of Cubicin® (daptomycin for injection) 500mg for intravenous (IV) infusion, following a customer complaint that a piece of glass was found in a vial after the drug had been reconstituted from its freeze-dried form.
- There is no impact to members through Benecard Central Fill.
- Cubicin is an antibiotic primarily used in hospitals and other monitored healthcare settings to treat bloodstream infections and complicated skin and skin structure infections.
- The presence of glass particles in a drug meant for IV infusion could harm patients if the particles enter the patient’s body. Consequences can range from local irritation to potentially fatal clotting and blockages in blood vessels.
- Merck had not received any reports of adverse events tied to the affected product as of the recall date. Healthcare professionals are advised via the drug’s label to inspect Cubicin for particulate matter prior to administration as part of standard preparations for use.
- Questions regarding this recall can be directed to the Merck National Service Center at 1-800-672- 6372, prompt #1. Merck recommends patients speak to their healthcare provider if they have experienced any problems that may be related to the use of the recalled Cubicin.
- The full recall announcement can be found the U.S. FDA's website.